Idiopathic focal segmental glomerulosclerosis
Conditions
Interventions
Tacrolimus group:Low dose of tacrolimus combined with hormone
hormone group:Use hormones
Sponsors
Southwest Hospital, the First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) The subjects participated voluntarily, signed informed consent, and indicated that they were willing to accept both treatments; (2) Aged 13 to 60 years; (3) Idiopathic FSGS was confirmed by clinical and renal biopsy; (4) Urine protein quantity was more than 1000mg / 24h; (5) No immunosuppressant was used within 1 month before treatment; (6) All patients were treated with angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II receptor 1 blocker (ARB). (7) Be able to follow the research or follow-up procedures.
Exclusion criteria
Exclusion criteria: (1) Women with recent family planning, pregnancy or lactation; (2) Failure to understand the potential risks and benefits of the study and follow-up assessment as required; (3) No capacity for civil conduct; (4) History of drug or alcohol abuse; (5) Second, hepatitis B, Henoch Schonlein purpura, systemic lupus erythematosus and other secondary FSGS; (6) Hereditary nephropathy such as family history of nephropathy; (7) The immunosuppressants including azathioprine, mycophenolate mofetil, cyclosporine A and leflunomide were taken within one month before the start of the study; (8) Patients with severe infection, tumor, or other conditions considered unsuitable for clinical study by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urine protein quantification; | — |
Countries
China
Contacts
Public ContactHongwen Zhao
Southwest Hospital, the First Affiliated Hospital of Army Medical University
Outcome results
None listed